Elucid Digital Health’s Pill Connect dispensing system provides CROs and pharma the ability to show adherence across the whole trial, by country, by site even down to the individual patient number in real time.
The dashboard is automatically created by the dispensing of the pill/tablet through the intelligent Pill Connect cap which fits on any standard pill bottle. The patient receives a reminder on their phone when the pill or pills should be taken. The patient then touches the dispense button on the screen and the pill is ejected from the bottle and a signal is sent, via the phone, that the pill has been dispensed. If the patient does not respond to the alert a reminder text or even a call can be made to prompt them or find out why. The patient does have the opportunity to respond to the alert by tapping on the screen that they don’t feel well or that the pills are upsetting them.
All of this information is collected in real time and the dashboard can be customized to show what ever data is requested by the CRO, or pharma.
Stuart Young, CEO of Panthera site management organization, commented, “Confident tracking and adherence to treatment needs this type of improvement to help ensure that the power of a study is not compromised. Investigators will really like this technology and it is simple to use and understand. We need more technology in research like this which is focused on the patient.”
Unfortunately, patients who do not adhere to the agreed regime have been known to mislead the trial monitors which can really effect the results of the trial.
CEO of Elucid, James Burnstone, commented, “We have had a lot of interest from some of the largest pharmas and CROs as the device is not only simple and inexpensive but also provides a great deal of information on the dispensing pattern. If, for instance, we note that Saturday morning is a problem because the patient is playing a sport we can work with the patient to find a solution which fits in with the protocol.”
Another benefit of the Pill Connect system is that it prevents double dosing-a real problem with some older patients. Once a pill is dispensed the cap locks until the next dose is due.
As well as providing a customized dashboard for the monitoring organizations the system also can show the patient in graphic form how they are doing and rate them compared to other people in the trial.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.